PRESS RELEASES

ROKOTE LABORATORIES LICENSES CEVEC’S CAP® AD TECHNOLOGY FOR VACCINE MANUFACTURING

  • ROKOTE Laboratories Finland Ltd to use CEVEC’s CAP® Ad viral vector technology for manufacturing therapeutic and prophylactic vaccines for COVID-19 and other respiratory diseases
  • By eliminating the risk of RCA contaminations, CAP® Ad-derived viral vectors provide highest safety, addressing one of the major challenges in vector-based vaccine production

Cologne, Germany and Helsinki and Kuopio, Finland – September 20, 2022

CEVEC’S LICENSE PARTNER RZNOMICS INC. RECEIVES APPROVAL TO INITIATE CLINICAL DEVELOPMENT OF CAP® AD TECHNOLOGY-PRODUCED GENE THERAPY VECTOR IN LIVER CANCER PATIENTS

  • RZNOMICS uses CEVEC’s CAP® Ad viral vector manufacturing technology for manufacturing gene therapy vectors targeting various cancer indications
  • South Korean Ministry of Food and Drug Safety granted IND approval for a clinical phase 1/2a trial to evaluate safety and efficacy of RZNOMICS lead gene therapy RZ001 for the treatment of primary liver cancer
  • Another important milestone has been reached for CEVEC’s unique CAP® cell line which enables by design the efficient production of high-quality, RCA-free adenoviral vectors

 Cologne, Germany – July 13, 2022

CEVEC AND UCB SIGN AGREEMENT FOR THE USE OF CEVEC’S ELEVECTA® AAV MANUFACTURING TECHNOLOGY IN GENE THERAPY

  • The ELEVECTA® Technology produces Stable Producer Cell Lines designed to enable fully scalable, high-performance AAV vector production
  • Under the agreement, CEVEC grants UCB rights and options to the ELEVECTA® Technology for the research, development and manufacturing of AAV gene therapy products

Cologne, Germany – September 7, 2021

CEVEC CLOSES GROWTH FINANCING ROUND TO SERVE STRONG DEMAND IN VIRAL VECTOR TECHNOLOGIES FOR CELL AND GENE THERAPIES

  • With its highly scalable Adenovirus and AAV production technologies, CEVEC provides cutting-edge manufacturing solutions for two of the most widely used gene therapy vectors
  • Funding will expand cell line development capacities for ELEVECTA® stable AAV
    producer cell lines
  • With ELEVECTA® currently being implemented in a second host cell type, an even stronger demand is expected

Cologne, Germany – July 27, 2021

CEVEC AND CARISMA THERAPEUTICS SIGN LICENSE AGREEMENT FOR THE USE OF CAP® TECHNOLOGY IN ANTI-TUMOR CELL THERAPIES

  • CARISMA receives full rights to use the CAP® Technology for the production of adenoviral vectors across their whole portfolio of cell therapies for oncology applications
  • CEVEC’s unique CAP® cells are specifically designed for highly scalable, RCA-free adenoviral vector manufacturing in suspension bioreactors
  • The agreement supports CARISMA’s development of novel CAR-macrophage immunotherapies, a first-of-its-kind approach to the treatment of solid tumors

Cologne, Germany and Philadelphia, PA – February 2, 2021

CEVEC ANNOUNCES NEW LICENSE AGREEMENT FOR ITS AAV MANUFACTURING TECHNOLOGY ELEVECTA® IN GENE THERAPY

  • Under the agreement CEVEC grants Biogen rights to its proprietary ELEVECTA® Technology for manufacturing of gene therapy products
  • ELEVECTA® stable producer cell lines enable fully scalable, helper virus-free AAV vector production in suspension bioreactors

Cologne, Germany – January 8, 2021

CEVEC SIGNS AGREEMENT WITH ROCHE FOR THE USE OF CEVEC’S ELEVECTA® TECHNOLOGY IN GENE THERAPY

Agreement will allow Roche to use CEVEC’s unique and proprietary ELEVECTA® Technology for AAV vector manufacturing

  • The ELEVECTA® Stable Producer Cell Lines are designed to enable fully scalable, high-performance biopharmaceutical industry

Cologne, Germany – November 10, 2020

CEVEC AND RZNOMICS SIGN LICENSE AGREEMENT FOR THE USE OF CAP® TECHNOLOGY IN MANUFACTURING OF ADENOVIRAL VECTORS

  • Rznomics will use the technology for gene therapies based on their proprietary trans-splicing ribozyme technology targeting various cancer indications
  • CEVEC’s unique CAP® cell line enables by design the efficient production of high-quality adenoviral vectors

Cologne, Germany and Yongin, Korea – October 19, 2020

CEVEC ANNOUNCES THE LAUNCH OF THE ELEVECTA® PLATFORM – THE STABLE PRODUCER CELL LINE TECHNOLOGY FOR AAV GENE THERAPY VECTORS

  • ELEVECTA® takes viral vector manufacturing to the next level to serve the rapidly growing market of gene therapy applications
  • Growing serum-free in suspension, ELEVECTA® producer cell lines enable fully scalable high-performance AAV vector production based on standardized processes widely used in industry for monoclonal antibody production
  • With all components stably integrated into one cell, the ELEVECTA® technology provides large scale AAV production without expensive cGMP-grade plasmids and complex transient transfection steps

 Cologne, Germany – April 28, 2020

CEVEC SIGNS LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF EXOSOMES FOR THERAPEUTIC USE

  • Agreement with Evox Therapeutics supports the utility of CAP® technology in the production of exosomes
  • Exosomes offer distinct advantages as highly effective drug carriers
  • Evox Therapeutics intends to develop CAP®-derived exosomes for several disease areas and indications

Cologne, Germany – April 16, 2020

© CEVEC Pharmaceuticals GmbH 2022